PeptideSearch

Liraglutide

Approved medicine

Get notified when the evidence changes.

The FDA has approved a version of this as a medicine, so it has been through large studies in people.

Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-04-30

Also called Saxenda / Victoza / NN2211

An approved daily injection for weight loss and type 2 diabetes.

Official status: Not nominated for 503A compounding · Checked 2026-04-30

Can a doctor prescribe this?

Small pharmacy (503A)
Never put forward to FDA
Large outsourcing facility (503B)
Never put forward to FDA

Approved and prescription-only. In April 2026 the FDA proposed removing it from the list large-scale compounders may use.

503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.

Doses used in research

Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.

This is a sample, not the whole literature.

About 21,000 papers mentioning this compound have been published. We show a selected sample of 110 of them, not the full literature. How we choose them · count checked 2026-08-23

Spot an error? corrections@peptidesearch.org

We'll email you when a new study, trial or status change lands for Liraglutide. Unsubscribe in one click.